Anna L. Heilig

Anna L. Heilig

Auto-generated profile, based on publicly available information

Anna L. Heilig

Department of Biomedical Data Science, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
AHAnna L. Heilig
Anna L. Heilig
MMM. Elske van den Akker-van Marle
M. Elske van den Akker-van Marle
FOFloris van Overveld
Floris van Overveld
CMCaroline Meijer
Caroline Meijer
MMM. Luisa Mearin
M. Luisa Mearin
JSJan M. Heijdra Suasnabar
Jan M. Heijdra Suasnabar
INTRODUCTION: Celiac disease (CD) may affect quality of life (QoL), health care use, and societal costs in various ways both before and after diagnosis. However, detailed evidence remains limited about how costs and QoL change after diagnosis and which patient characteristics (e.g., symptom duration) influence those changes. The aim of this study was to evaluate CD patients' QoL and societal costs before and after diagnosis. METHODS: In this cross-sectional study, 2,691 patient-members of the Dutch Celiac Society completed a questionnaire about their life before and after diagnosis. Data collection included sociodemographic and clinical characteristics, health care use, non–health care costs, and QoL (measured using the EuroQol 5-Dimension 5-Level). Mean QoL and annual health care and societal costs were compared prediagnosis and postdiagnosis. Multivariate regression models were used to identify factors associated with QoL and costs in both periods (and difference between periods). RESULTS: On average, respondents recalled experiencing 4–5 symptoms before diagnosis. QoL improved significantly postdiagnosis, with greater improvements among childhood diagnoses. Annual health care and societal costs decreased by 23% and 36%, respectively, postdiagnosis, except for societal costs in those diagnosed during childhood. Age at diagnosis and the number of prediagnosis symptoms were associated with lower and higher recalled prediagnosis QoL, respectively. Number of symptoms, comorbidities, and nonadherence to a gluten-free diet were associated with lower postdiagnosis QoL. DISCUSSION: After CD diagnosis, QoL significantly improved and health care and societal costs decreased, except for societal costs among childhood diagnoses. These findings enhance the understanding of CD's burden and economic impact, supporting health care and policy efforts for timely CD identification.

26 May 2026 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
AHAnna L. Heilig
Anna L. Heilig
WHWilbert B. van Den Hout
Wilbert B. van Den Hout
MMM. Elske van den Akker-van Marle
M. Elske van den Akker-van Marle
Background and Objective Remote patient monitoring has shown promising outcomes, such as improved disease awareness and reduced hospital stay. However, assessing the cost of the remote patient monitoring itself is challenging owing to the lack of standardization and transparency in economic evaluations of remote patient monitoring. This review aims to identify and compare the cost components used to estimate the remote patient monitoring intervention costs and the reported challenges in assessing them. Methods We performed a scoping review of studies published in PubMed, Embase, and Web of Science that conducted an economic evaluation of a remote patient monitoring between January 2019 and March 2026. Titles and abstracts were screened. Relevant articles were subjected to full-text screening to assess eligibility, and reported cost components were counted based on predefined categories. Difficulties reported by the economic evaluation authors (challenges) were extracted and analyzed using thematic synthesis. Results A total of 1282 articles were identified, of which 84 studies met the eligibility criteria. Forty-nine (58%) studies had an observational design, and the remaining studies had a model design. Components of remote patient monitoring intervention costs were reported in 71 (85%) of the included studies, with staff salaries (62%) and equipment/technology (56%) costs being the most frequently reported. The most commonly reported challenge was uncertainty about which remote patient monitoring cost categories to include. Conclusions This review highlights the disparities in the assessment and reporting of remote patient monitoring intervention costs in economic evaluations. We offer an updated checklist and guidance for assessing and reporting intervention costs in future economic evaluations.

15 July 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AHAnna Heilig
Anna Heilig
TBTobias Bonten
Tobias Bonten
KRKasper Recourt
Kasper Recourt
MMM. Elske van den Akker-van Marle
M. Elske van den Akker-van Marle
The rapid expansion of remote patient monitoring (RPM) interventions highlights the need for their comparison and evaluation. Current evaluation frameworks often fail to capture a multistakeholder perspective. Traditional health technology assessment approaches emphasize health and economic outcomes, providing an incomplete picture of RPM's broader impact. The Sextuple Aim, encompassing health outcomes, costs, patient and provider experience, equity, and sustainability, offers a more comprehensive approach. Yet, the specific aspects that are important for capturing each domain for diverse stakeholders, and that could form a core outcome set (COS) for RPM evaluation, remain undefined. This study aimed to identify the most important value aspects for evaluating RPM interventions from the Sextuple Aim domains. Value aspects relevant to evaluating RPM interventions within the Sextuple Aim framework were identified in a review of the literature, and this initial set was refined through stakeholder meetings. Subsequently, 6 stakeholder groups completed 3 Delphi rounds. Patients and informal caregivers (25-30 respondents per group) were recruited via a patient federation. Health care providers (20-30 experts), managers, insurers, and researchers (10-20 experts per group) were recruited. In each round, participants rated the importance of aspects on a 5-point Likert scale. In round 2, participants ranked aspects within each domain to determine their relative importance; in round 3, they ranked aspects across domains. A multicriteria consensus rule was used to select aspects for the preliminary COS. The COS was finalized during a multistakeholder expert meeting with 7 experts. Of the 171 respondents, 137 (80%) completed all Delphi rounds. The input set, formed through a literature search and meetings, contained 43 value aspects. The total set contained 47 aspects after the first round. After all 3 rating rounds, 33 of 47 (70%) value aspects met the predefined importance threshold. Ranking results from rounds 2 and 3 identified aspects prioritized within and across domains. In total, 26 (55%) aspects met the multicriteria consensus rule and formed the preliminary COS. During the final multistakeholder expert meeting involving subgroup exercises and moderated discussions, value aspects with conceptual overlap were merged, removed, or relocated. The final COS included 17 value aspects, with 1 additional emergent aspect identified during the expert meeting and included as a recommended item, which also resulted in full Sextuple Aim domain coverage. An RPM Sextuple Aim COS comprising 17 value aspects and 1 recommended aspect was developed, providing a multidimensional and multistakeholder evaluation set. This COS provides a standardized, comprehensive basis for evaluating RPM interventions and can be used to support the validation and refinement of existing RPM evaluation tools. Future research may consider operationalizing the COS and its recommended aspect into measurable items and assessing its feasibility and uptake in practice.